TY - JOUR
T1 - Nanomedicinal delivery of stimulator of interferon genes agonists
T2 - Recent advances in virus vaccination
AU - Chattopadhyay, Saborni
AU - Hu, Che Ming Jack
N1 - Funding Information:
The authors acknowledge funding support by the Ministry of Science and Technology, Taiwan (106-2119-M-001-010, 107-2119-M-001-042, 108-2119-M-001-016) and Academia Sinica Career Development Award (AS-CDA-105-L06). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2020
PY - 2020/12
Y1 - 2020/12
N2 - The discovery of stimulator of interferon genes (STING) and their agonists as primary components that link antiviral innate and adaptive immunity has motivated growing research on STING agonist-mediated immunotherapy and vaccine development. To overcome the delivery challenge in shuttling highly polar STING agonists, typically in the form of cyclic dinucleotides, to target cells and to STING proteins in cellular cytosol, numerous nanoformulation strategies have been implemented for effective STING activation. While many STING-activating nanoparticles are developed to enhance anticancer immunotherapy, their adoption as vaccine adjuvant has vastly propelled antiviral vaccination efforts against challenging public health threats, including HIV, influenza and coronaviruses. In light of the COVID-19 pandemic that has thrusted vaccine development into the public spotlight, this review highlights advances in nanomedicinal STING agonist delivery with an emphasis on their applications in antiviral vaccination.
AB - The discovery of stimulator of interferon genes (STING) and their agonists as primary components that link antiviral innate and adaptive immunity has motivated growing research on STING agonist-mediated immunotherapy and vaccine development. To overcome the delivery challenge in shuttling highly polar STING agonists, typically in the form of cyclic dinucleotides, to target cells and to STING proteins in cellular cytosol, numerous nanoformulation strategies have been implemented for effective STING activation. While many STING-activating nanoparticles are developed to enhance anticancer immunotherapy, their adoption as vaccine adjuvant has vastly propelled antiviral vaccination efforts against challenging public health threats, including HIV, influenza and coronaviruses. In light of the COVID-19 pandemic that has thrusted vaccine development into the public spotlight, this review highlights advances in nanomedicinal STING agonist delivery with an emphasis on their applications in antiviral vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85098551269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098551269&partnerID=8YFLogxK
U2 - 10.2217/nnm-2020-0269
DO - 10.2217/nnm-2020-0269
M3 - Review article
C2 - 33252301
AN - SCOPUS:85098551269
SN - 1743-5889
VL - 15
SP - 2883
EP - 2894
JO - Nanomedicine
JF - Nanomedicine
IS - 29
ER -
